SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS shares drew attention after a sharp selloff without a cited company update; traders attributed the move to options expiration, broader biotech weakness, and possible short-selling or stop-loss activity, though these explanations are speculative. The decline intensified debate over the prolonged quiet period and pending REGAL Phase 3 readout: some investors are buying the dip and anticipating positive data, while others are concerned about the lack of updates and trial uncertainty.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas next-generation Roadster reveal, featuring SpaceX-derived thrusters and airborne stunts, is driving discussion: some traders praise the engineering and potential TeslaSpaceX synergies, while others call it an impractical concept with little commercial or near-term earnings impact. Merger speculation remains unconfirmed, and enthusiasm has been tempered by the stocks fade from its premarket rise.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is under pressure amid a broad memory-chip and semiconductor selloff, as traders debate whether Chinese competition and doubts about AI investment returns could weaken the memory boom; volatility and foreign selling in South Koreas market are adding to concerns. The community is split between those expecting further downside from a normalizing memory cycle and buyers who view the decline as overdone, arguing that HBM demand remains strong and the competitive threat is overstated.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas sharp pullback after a steep rally has traders debating profit-taking and valuation, with some also pointing to insider share sales; bulls view the decline as a dip while bears warn the run may be overextended. The main focus remains the upcoming full Phase 3 melanoma cancer-vaccine data, which traders see as a potential catalyst but also a risk for a sell-the-news reaction.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Concerns about CoreWeaves heavy borrowing and rising bond yields are driving debate over whether its AI infrastructure expansion can generate enough cash to service its debt, contributing to sharp selling and volatile rebounds. Some traders see Nvidia CEO Jensen Huangs reassurance and bullish analyst views as support for buying the dip, while others remain worried about refinancing, dilution, and default risk.

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

Golds volatile pullback and rebound amid hotter inflation data and shifting Fed rate-hike expectations are driving discussion, with traders linking pressure on the metal to rising yields and a stronger dollar. Views are divided between those buying the dip or expecting a recovery as yields ease and those warning that persistent rate pressures could weigh on gold further.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention amid a sharp semiconductor-sector selloff, with traders citing hotter inflation and rate concerns, scrutiny of AI spending and valuations, and weakness in chip stocks and Asian markets. The community is divided between buying an oversold dip in hopes of a rebound and expecting further declines; the funds 3 leverage amplifies the volatility.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is caught in a broader AI and semiconductor selloff as traders question whether debt-financed data-center spendingespecially amid CoreWeaves financing concernswill generate sustainable returns. The community is divided between buying the pullback on continued chip-demand signals and worrying that tighter financing and weaker investment returns could pressure the AI trade.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is under pressure after Citi reiterated its Sell rating and raised its price target, while traders also debated a circulating report of an FDA pause in a key trial that some said was false. The selloff has fueled frustration and claims of short- or algorithm-driven trading, while other traders are treating the drop as a buying opportunity.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Goldman Sachs upgrade of Zeta to Buy, alongside several other analyst target increases, is fueling attention and optimism about its AI-driven marketing platform and enterprise growth. Traders are debating the pullback after a run to new highs, attributing it variously to profit-taking and options expiration while others remain bullish ahead of earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.read more...

Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study

MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.

Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?

Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study

Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?

Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why You Should Add ARQT Stock to Your Portfolio Now

Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen 

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.


5 Biotech Stocks Worth Adding to Your Portfolio Now 

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector. 

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +22.22% and +6.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Viatris Gears Up to Report Q2 Earnings: What's in the Cards?

VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally

Equity

Bullish Sentiment

50bps hike

25bps hike

No change

Rate cut

September CPI rose 0.6% from the prior month to 3.7% annually, while producer prices jumped 6.3% year-over-year, the biggest gain since 2022, putting the Federal Reserve's October 27-28 meeting squarely in focus after its first rate hike in three years last month. What does the Fed do at its October meeting? Vote and explain your reasoning in the comments.

September CPI hit 3.7% and PPI jumped 6.3%, both hotter than expected. What does the Fed do at its October meeting?

Stocktwits

Stocktwits Polls

$ARQT 
Yup yup yup.... The closer to earnings the higher the SP will get. Book it. 
Fucking clowns dont want to get caught shorting a winner like last time.

Fire_Truck

$ARQT The volatility with this stock is suspicious.  I don’t understand why it keeps fluctuating so much down and then up on no public information. I know many people suspect shenanigans by the toots, which is possible.  The fair intrinsic value is about $35 - 40 per share.

$ARQT So, explain to me why the SEC knowingly allows Market Makers to sell 141.2 million shares out of a total of 126 million issued shares and to keep their naked short position open for 10 months when the law requires any naked short position to be closed out in a maximum of 3 days?

wesley thompson

$ARQT The MM Mafia desperately needs sellers to cover their estimated 45+ million counterfeit share open naked short positions. (Add Imstitutional short positions of 20 million shares and the entire retail investor inventory of shares bc institutional ownership alone is 112.5% of all issued shares), because the Mafiosi only get sellers by dropping their Bid & Ask.

$ARQT Congrats on the addition to the SmallCap 600 tomorrow 🔥
That’s an overlooked index with listing requirements that weed out weaklings

Enrico Palazzo

$ARQT biggest volume never seen here,  in day trade and even in ah !!! 
SOMETHING BIG IS HAPPENING,  STAY TUNED !!! 
🚀🚀🚀🚀🚀💥💥💥💥💥

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARQT Arcutis Biotherapeutics Inc

Fundamentals

Latest ARQT News